Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Selective Serotonin Reuptake Inhibitor (SSRI) Use during Pregnancy and Effects on the Fetus and Newborn: A Meta-Analysis

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are frequently used to treat depression during pregnancy and the postpartum period. These drugs are capable of crossing the placenta and being transferred to the newborn during lactation. This report reviews the available information regarding the effects of SSRIs on the fetus and newborn; including long-term neurodevelopmental outcomes.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Burke KC, Burke Jr JD, Rae DS, Regier DA . Comparing age at onset of major depression and other psychiatric disorders by birth cohorts in five US community populations. Arch Gen Psychiatry 1991;48:789–795.

    Article  CAS  Google Scholar 

  2. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8–19.

    Article  CAS  Google Scholar 

  3. Wisner KL, Perel JM . Psychopharmacological treatment during pregnancy and lactation. In: Jensvold MF, Halbreich U, Hamilton JA, editors. Psychopharmacology and Women: Sex, Gender and Hormones. Washington DC: American Psychiatric Press; 1996. pp. 191–224.

    Google Scholar 

  4. Field T . Infants of depressed mothers. Infant Behav Dev 1995;18:1–13.

    Article  Google Scholar 

  5. Marcus SM, Flynn HA, Blow FC, KL . Depressive symptoms among pregnant women screened in obstetrics settings. J Womens Health (Larchmt) 2003;12:373–380.

    Article  Google Scholar 

  6. Lundy B, Jones N, Field T, et al. Prenatal depression effects on neonates. Infant Behav Dev 1999;22:119–129.

    Article  Google Scholar 

  7. Preti A, Cardascia L, Tiziana Z, et al. Obstetric complications in patients with depression—a population-based case-control study. J Affective Disord 2000;61:101–106.

    Article  CAS  Google Scholar 

  8. Dayan J, Creveuil C, Herlicoviez M, et al. Role of anxiety and depression in the onset of spontaneous preterm labor. Am J Epidemiol 2002;155:293–301.

    Article  CAS  Google Scholar 

  9. Orr ST, James SA, Blackmore-Prince C . Maternal prenatal depressive symptoms and spontaneous preterm births among African-American women in Baltimore, Maryland. Am J Epidemiol 2002;156:797–802.

    Article  Google Scholar 

  10. Hoffman S, Hatch M . Depressive symptomatology during pregnancy: evidence for an association with decreased fetal growth in pregnancies of lower social class women. Health Psychol 2000;19:535–543.

    Article  CAS  Google Scholar 

  11. Kurki T, Hiilesmaa V, Raitasalo R, Mattila H, Ylikorkala O . Depression and anxiety in early pregnancy and risk for preeclampsia. Obstet Gynecol 2000;95:487–490.

    CAS  PubMed  Google Scholar 

  12. Vaswani M, Linda FK, Ramesh S . Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:85–102.

    Article  CAS  Google Scholar 

  13. Whitaker-Azmitia PM, Druse M, Walker P, Lauder JM . Serotonin as a developmental signal. Behav Brain Res 1996;73:19–29.

    Article  CAS  Google Scholar 

  14. Pohland RC, Byrd TK, Hamilton M, Koons JR . Placental transfer and fetal distribution of fluoxetine in the rat. Toxicol Appl Pharmacol 1989;98:198–205.

    Article  CAS  Google Scholar 

  15. Costa LG, Steardo L, Cuomo V . Structural effects and neurofunctional sequelae of developmental exposure to psychotherapeutic drugs: experimental and clinical aspects. Pharmacol Rev 2004;56:103–147.

    Article  CAS  Google Scholar 

  16. Cabrera-Vera TM, Battaglia G . Prenatal exposure to fluoxetine (Prozac) produces site-specific and age-dependent alterations in brain serotonin transporters in rat progeny: evidence from autoradiographic studies. J Pharmacol Exp Ther 1998;286:1474–1481.

    CAS  PubMed  Google Scholar 

  17. Hansson SR, Mezey E, Hoffman BJ . Serotonin transporter messenger RNA expression in neural crest-derived structures and sensory pathways of the developing rat embryo. Neuroscience 1999;89:243–265.

    Article  CAS  Google Scholar 

  18. Anderson GM . Peripheral and central neurochemical effects of the selective serotonin reuptake inhibitors (SSRIs) in humans and nonhuman primates: assessing bioeffect and mechanisms of action. Int J Dev Neurosci 2004;22:397–404.

    Article  CAS  Google Scholar 

  19. Addis A, Koren G . Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. Psychol Med 2000;30:89–94.

    Article  CAS  Google Scholar 

  20. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL . Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996;335:1010–1015.

    Article  CAS  Google Scholar 

  21. Heikkinen T, Ekblad U, Laine K . Transplacental transfer of citalopram, fluoxetine and their primary demethylated metabolites in isolated perfused human placenta. Br J Obstet Gynecol 2002;109:1003–1008.

    Article  CAS  Google Scholar 

  22. Hendrick V, Stowe ZN, Altshuler LL, et al. Placental passage of antidepressant medications. Am J Psychiatry 2003;160:993–996.

    Article  Google Scholar 

  23. Heikkinen T, Ekblad U, Kero P, Ekblad S, Laine K . Citalopram in pregnancy and lactation. Clin Pharmacol Ther 2002;72:184–191.

    Article  Google Scholar 

  24. Isbister GK, Dawson A, Whyte IM, et al. Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome? Arch Dis Child Fetal Neonatal Ed 2001;85:F147–F148.

    Article  CAS  Google Scholar 

  25. Haddad PM . Antidepressant discontinuation syndromes. Drug Saf 2001;24:183–197.

    Article  CAS  Google Scholar 

  26. Sternbach H . The serotonin syndrome. Am J Psychiatry 1991;148:705–713.

    Article  CAS  Google Scholar 

  27. Oberlander TF, Misri S, Fitzgerald CE, et al. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 2004;65:230–237.

    Article  CAS  Google Scholar 

  28. Kallen B . Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004;158:312–316.

    Article  Google Scholar 

  29. Simon GE, Cunningham ML, Davis RL . Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002;159:2055–2061.

    Article  Google Scholar 

  30. Ericson A, Kallen B, Wiholm B . Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999;55:503–508.

    Article  CAS  Google Scholar 

  31. Suri R, Altshuler L, Hendrick V, et al. The impact of depression and fluoxetine treatment on obstetrical outcome. Arch Women's Mental Health 2004;7:193–200.

    Article  CAS  Google Scholar 

  32. Zeskind PS, Stephens LE . Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004;113:368–375.

    Article  Google Scholar 

  33. Hendrick V, Smith LM, Suri R, et al. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 2003;188:812–815.

    Article  CAS  Google Scholar 

  34. Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002;159:1889–1895.

    Article  Google Scholar 

  35. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998;279:609–610.

    Article  CAS  Google Scholar 

  36. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997;336:258–262.

    Article  CAS  Google Scholar 

  37. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993;269:2246–2248.

    Article  CAS  Google Scholar 

  38. Zeskind PS, Stephens LE . Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004;113:368–375.

    Article  Google Scholar 

  39. Costei AM, Kozer E, Ho T, Ito S, Koren G . Perinatal outcome following third trimester exposure to paroxetine. [See comment]. Arch Pediatr Adolesc Med 2002;156:1129–1132.

    Article  Google Scholar 

  40. Goldstein DJ . Effects of third trimester fluoxetine exposure on the newborn. J Clin Psychopharmacol 1995;15:417–420.

    Article  CAS  Google Scholar 

  41. Costei AM, Kozer E, Ho T, Ito S, Koren G . Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002;156:1129–1132.

    Article  Google Scholar 

  42. Cohen LS, Heller VL, Bailey JW, et al. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatr 2000;48:996–1000.

    Article  CAS  Google Scholar 

  43. Casper RC, Fleisher BE, Lee-Ancajas JC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003;142:402–408.

    Article  CAS  Google Scholar 

  44. Hendrick V, Smith LM, Suri R, et al. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 2003;188:812–815.

    Article  CAS  Google Scholar 

  45. Chambers C, Dick LM, Felix RJ, Johnson KA, Jones KL . Pregnancy Outcome in women who use sertraline. Teratology 1999;59:376.

    Google Scholar 

  46. Goldstein DJ, Corbin LA, Sundell KL . Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 1997;89:713–718.

    Article  CAS  Google Scholar 

  47. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993;269:2246–2248.

    Article  CAS  Google Scholar 

  48. Einarson A, Fatoye B, Sarkar M, et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 2001;158:1728–1730.

    Article  CAS  Google Scholar 

  49. Laine K, Heikkinen T, Ekblad U, Kero P . Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003;60:720–726.

    Article  CAS  Google Scholar 

  50. Aranda J, Edwards D, Hales B, Rieder M . Developmental pharmacology. In: Fanaroff AA, Martin RJ, editors. Neonatal-Perinatal Medicine: Diseases of the Fetus and Infant. 7th ed. St. Louis: Mosby; 2002. p. 145.

    Google Scholar 

  51. Weissman AM, Levy BT, Hartz AJ, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry 2004;161:1066–1078.

    Article  Google Scholar 

  52. Berle JO, Steen VM, Aamo TO, et al. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes. J Clin Psychiatry 2004;65:1228–1234.

    Article  CAS  Google Scholar 

  53. Hendrick V, Stowe ZN, Altshuler LL, et al. Fluoxetine and norfluoxetine concentrations in nursing infants and breast milk. Biol Psychiatry 2001;50:775–782.

    Article  CAS  Google Scholar 

  54. Stowe ZN, Hostetter AL, Owens MJ, et al. The pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations. J Clin Psychiatry 2003;64:73–80.

    Article  CAS  Google Scholar 

  55. Heikkinen T, Ekblad U, Palo P, Laine K . Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther 2003;73:330–337.

    Article  CAS  Google Scholar 

  56. Chambers CD, Anderson PO, Thomas RG, et al. Weight gain in infants breastfed by mothers who take fluoxetine. Pediatrics 1999;104:e61.

    Article  CAS  Google Scholar 

  57. Oberlander TF, Eckstein Grunau R, et al. Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response. Pediatr Res 2002;51:443–453.

    Article  CAS  Google Scholar 

  58. Morag I, Batash D, Keidar R, et al. Paroxetine use throughout pregnancy: does it pose any risk to the neonate? J Toxicol Clin Toxicol 2004;42:97–100.

    Article  CAS  Google Scholar 

  59. Zeskind PS, Oberlander TF, Grunau RE, et al. Continuing effects of prenatal SSRI exposure detected by spectral analysis of infant cry sounds at two months of age. Pediatr Res 2005;57:1624A.

    Google Scholar 

Download references

Acknowledgements

This research was supported by the National Institute of Mental Health, MH065062 to DMV, CRN and NK; and MH068489 to DMV and CRN. We thank Robert Schumacher, MD for his helpful comments during the preparation of this manuscript.

Author information

Authors and Affiliations

Authors

Additional information

Charles R. Neal, Jr., MD, PhD is presently at the University of Hawaii John A. Burns School of Medicine.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lattimore, K., Donn, S., Kaciroti, N. et al. Selective Serotonin Reuptake Inhibitor (SSRI) Use during Pregnancy and Effects on the Fetus and Newborn: A Meta-Analysis. J Perinatol 25, 595–604 (2005). https://doi.org/10.1038/sj.jp.7211352

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jp.7211352

This article is cited by

Search

Quick links